PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 692-697

  Kolasa, I K ^a   Rembiszewska, A ^a   Janiec Jankowska, A ^a   Dansonka Mieszkowska, A ^a   Lewandowska, A M ^a   Konopka, B ^a   Kupryjanczyk J ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

BRCA1; K RAS; Ovarian cancer; PTEN; TP53

Indexed keywords

BRCA1 PROTEIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN P53;

ARTICLE; CANCER RISK; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; EVALUATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MOLECULAR DYNAMICS; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; FEMALE; GENES, BRCA1; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MUTATION; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 33750185399     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.05.007     Document Type: Article

References (38)

1. Schuijer M., and Berns E.M. TP53 and ovarian cancer. Hum. Mutat. 21 (2003) 285-291
2. Kupryjanczyk J. TP53 status determines prognostic and predictive factors in ovarian carcinomas. In: Bardos A.P. (Ed). Trends in ovarian cancer research (2004), Nova Science Publishers, Inc 93-111
3. Menkiszak J., Gronwald J., Gorski B., Jakubowska A., Huzarski T., Byrski T., et al. Hereditary ovarian cancer in Poland. Int. J. Cancer 106 (2003) 942-945
4. Gemignani M.L., Schlaerth A.C., Bogomolniy F., Barakat R.R., Lin O., Soslow R., et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol. Oncol. 90 (2003) 378-381
5. Catasus L., Bussaglia E., Rodrguez I., Gallardo A., Pons C., Irving J.A., et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 35 11 (2004) 1360-1368
6. Kupryjanczyk J., Madry R., Plisiecka-Halasa J., Bar J., Kraszewska E., Ziolkowska I., et al. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br. J. Cancer 91 (2004) 1916-1923
7. Bast R.C., and Mills G.B. Molecular pathogenesis of ovarian cancer. In: Mendelsohn J., Howley P.M., Israel M.A., and Liotta L.A. (Eds). The molecular basis of cancer (2001), W.B. Saunders, Philadelphia 361-385
8. Plisiecka-Halasa J., Dansonka-Mieszkowska A., Rembiszewska A., Bidzinski M., Steffen J., and Kupryjanczyk J. Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumors. Ann. Hum. Genet. 66 (2002) 353-359
9. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
10. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15 (1997) 356-362
11. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
12. Minaguchi T., Mori T., Kanamori Y., Matsushima M., Yoshikawa H., Taketani Y., et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res. 59 (1999) 6063-6067
13. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 22 (2003) 183-198 [Review]
14. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
15. Ali I.U., Schriml L.M., and Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91 (1999) 1922-1932
16. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58 (1998) 2095-2097
17. Saito M., Okamoto A., Kohno T., Takakura S., Shinozaki H., Isonishi S., et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int. J. Cancer 85 (2000) 160-165
18. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 60 (2000) 7052-7056
19. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., and Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 158 (2001) 2097-2106
20. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11 (2005) 63-70
21. Inaba F., Kawamata H., Teramoto T., Fukasawa I., Inaba N., and Fujimori T. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol. Rep. 13 (2005) 17-24
22. Soyoola E.O., and Pattillo R.A. PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors. Am. J. Obstet. Gynecol. 188 (2003) S33-S36
23. Russell P. Surface epithelial-stromal tumors of the ovary. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract (1994), Spring-Verlag, Berlin 705-782
24. Risinger J.I., Hayes A.K., Berchuck A., and Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57 (1997) 4736-4738
25. Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 8 (1994) 399-404
26. Konopka B., Paszko Z., Janiec-Jankowska A., and Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett. 178 (2002) 43-51
27. Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjańczyk J, Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet (in press).
28. Hamilton J.A., Stewart L.M., Ajayi L., Gray I.C., Gray N.E., Roberts K.G., et al. The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers. Br. J. Cancer 82 (2000) 1671-1676
29. Kupryjanczyk J., Szymanska T., Madry R., Timorek A., Stelmachow J., Karpinska G., et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br. J. Cancer 88 (2003) 848-854
30. Parsa A.T., and Holland E.C. Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol. Med. 10 (2004) 607-613 [Review]
31. Lax S.F., Kendall B., Tashiro H., Slebos R.J., and Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000) 814-824
32. Freihoff D., Kempe A., Beste B., Wappenschmidt B., Kreyer E., Hayashi Y., et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br. J. Cancer 79 (1999) 754-758
33. Halachmi N., Halachmi S., Evron E., Cairns P., Okami K., Saji M., et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23 (1998) 239-243
34. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11563-11568
35. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1 (2003) E59
36. Schondorf T., Ebert M.P., Hoffmann J., Becker M., Moser N., Pur S., et al. Hypermethylation of the PTEN gene in ovarian cancer cell lines. Cancer Lett. 207 (2004) 215-220
37. Schondorf T., Hoopmann M., Eversheim B., Valter M.M., Becker M., Wappenschmidt B., et al. Expression of the tumor suppressor gene PTEN is not altered in the progression of ovarian carcinomas and does not correlate with p27Kip1 expression. Oncol. Rep. 10 (2003) 1717-1722
38. Lee S., Choi E.J., Jin C., and Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 97 (2005) 26-34